Pharmaceutical News

RSS

Navidea announces FDA extension of Lymphoseek PDUFA date by three months

Navidea Biopharmaceuticals, Inc. today announced that yesterday it received notification from the United States Food and Drug Administration (FDA) that the Prescription Drug User Fee Act (PDUFA) date for 99m-Tc-Tilmanocept, has been modified to September 10, 2012, a 90-day extension from the initial PDUFA date of June 10th.

4 Apr 2012

Researchers figure out how rapamycin causes diabetes

The drug known as rapamycin is widely used by cancer and transplant patients, and there are hints that it might even help us put off old age and live longer. But, it also comes with a downside: rapamycin leads to diabetes in as many as 15 percent of the people who take it.

4 Apr 2012

Mylan introduces Mesna Injection

Mylan Inc. today announced that its Mylan Institutional business has launched Mesna Injection, 100 mg/mL, packaged in 1,000 mg/10mL multiple-dose vials.

4 Apr 2012

TL32711 compound targets key pathway in lymphoma

Scientists at Fox Chase Cancer Center in Philadelphia have come one step closer to developing the first treatment to target a key pathway in lymphoma. The new findings will be announced at the AACR Annual Meeting 2012 on Tuesday, April 3.

4 Apr 2012

Federal Trade Commission OKs $29 billion merger by Express Scripts, Medco

By a three-to-one vote, regulators approved Express Scripts' plan to purchase Medco, ending an eight-month inquiry into whether the deal would stifle competition in the pharmacy benefits industry.

3 Apr 2012

Doctors more reluctant to start their patients on insulin

Doctors are more reluctant to start their patients on insulin than the patients are themselves, according to a new study led by researchers at St. Michael's Hospital.

3 Apr 2012

Prenatal antipsychotic drug exposure may reduce scores on infant neuromotor screening

Among 6-month-old infants, a history of intrauterine antipsychotic medication exposure was associated with significantly lower scores on a standard test of neuromotor performance, according to a report published Online First by Archives of General Psychiatry, a JAMA Network publication.

3 Apr 2012

Study shows how morphine creates inflammatory response in the brain

An international team of researchers involving the University of Adelaide and University of Colorado has made a major discovery that could lead to more effective treatment of severe pain using morphine.

3 Apr 2012

Older maternal age, fertility treatments account for marked increase in twin births

Women having children at older ages and the growing availability of fertility treatments has led to a marked increase in the birth of twins: In 2009, one in every 30 babies born in the United States was a twin compared with one in every 53 in 1980.

3 Apr 2012

State capitols: Social issues a hot topic; Iowa short on time for state budget; Kansas advances drug bills

Legislatures in Iowa and Kansas consider bills on health care, while Stateline looks at the social issues debates going on in many state capitols around the nation.

3 Apr 2012

TLR4/MD-2 protein complex triggers morphine-induced inflammation

A University of Colorado Boulder-led research team has discovered that two protein receptors in the central nervous system team up to respond to morphine and cause unwanted neuroinflammation, a finding with implications for improving the efficacy of the widely used painkiller while decreasing its abuse potential.

3 Apr 2012

Meda opens China affiliate based in Beijing

Meda has established an affiliate in Hong Kong. At the end of last year, Meda opened its China affiliate based in Beijing. Meda will begin by commercializing two of its well-established products in Hong Kong; Elidel for the treatment of atopic dermatitis (eczema) and azelastine for the treatment of allergic rhinitis.

3 Apr 2012

Combination treatment effective against melanoma

Research from The Cancer Institute of New Jersey (CINJ) shows that a coordinated effort to block signaling pathways that promote cancer cell growth and survival enhances programmed cell death in melanoma.

3 Apr 2012

UCB receives FDA approval for Neupro to treat idiopathic Parkinson's, RLS

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro (Rotigotine Transdermal System) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease (PD) and as a treatment for moderate-to-severe primary Restless Legs Syndrome.

3 Apr 2012

PET allows survival predictions in sarcoma after initial cycle of neoadjuvant chemo

An early Positron Emission Tomography (PET) response after the initial cycle of neoadjuvant chemotherapy can be used to predict increased survival in patients with soft tissue sarcomas, according to a study by researchers with UCLA's Jonsson Comprehensive Cancer Center.

3 Apr 2012

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

ARIAD Pharmaceuticals, Inc. today announced the presentation of new preclinical data on its investigational pan-BCR-ABL inhibitor, ponatinib, and its investigational dual EGFR-ALK inhibitor, AP26113, at the American Association for Cancer Research Annual Meeting in Chicago.

3 Apr 2012

CovalentMedical makes Focus MaculaPro available to general public

Focus MaculaPro is a leading macular health vitamin in the United States and is sold in more retina specialists' offices than any other eye vitamin on the market. Focus MaculaPro up until now has only been available to patients through their retina specialist. Now, however, Covalent Medical has made Focus MaculaPro available to the general public.

3 Apr 2012

New guidelines offer guidance on how and when to switch between RA drug classes

A trend toward more aggressive treatment in patients just starting to develop rheumatoid arthritis is among the most important changes in treatment guidelines for the disease, according to updated American College of Rheumatology recommendations published today in the journal Arthritis Care & Research. The trend may proceed from emerging opinions that joint damage caused by RA is irreversible, and that early, intensive therapy better preserves physical function, quality of life and capacity to work.

2 Apr 2012

Combination of Avastin and Metformin may effectively reduce melanoma growth

COMBINING the experimental drug Avastin (bevacizumab) with the diabetes drug Metformin almost doubles its ability to reduce skin cancer growth, according to a study in Cancer Discovery.

2 Apr 2012

Vaccines for measles may not increase risk of febrile seizures in 4-6 year olds

Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.

2 Apr 2012